P1vital

An innovative Clinical Research Organisation specialising in experimental medicine for Central Nervous System (CNS) disorders and obesity.

[P1vital @p1vital]

Abi Abrahams, the paper’s corresponding author and Senior Scientist at P1vital, will be presenting these results at the @sapcacuk Primary Care Mental Health Conference this week.
#depression #treatmentresistantdepression #TRD #UKprimarycare #mentalhealth

[P1vital @p1vital]

We’re pleased to share our paper on inadequate response to antidepressants in the UK, highlighting that many patients with low mood remain unwell 48 weeks after first receiving treatment, but often don’t seek further medical help despite ongoing symptoms.
https://t.co/68aZ8gFnp6

[P1vital @p1vital]

The previously-published efficacy results of the trial can be found here: https://t.co/DzsoskhEAR
https://t.co/VgXsv3oSRq

[P1vital @p1vital]

We're very excited to share our recent publication on the experiences of #NHS Intensive Care Unit staff in the GAINS-01 study.
#neuroscience #mentalhealth #healthtech #healthcare #mentalhealthtech
https://t.co/rh5PecAscM

[P1vital @p1vital]

GAINS-01 aimed to reduce recurrence of intrusive memories of trauma via a novel, neuroscience-informed imagery competing intervention. #ICU staff found the intervention easy to use, helpful, and highly acceptable, with potential to help overcome stigma about mental health at work

[P1vital @p1vital]

Together with #ISO 27001 and Cyber Essentials, our compliance displays our commitment to enhanced quality and excellence when collaborating with clients.
Get in touch to find out how we can support your study with quality at the core of what we do: https://t.co/IJQZDfrFpG

[P1vital @p1vital]

As we step into 2024, P1vital Products are pleased to share that we have achieved #ISO 9001 certification.
This means that we are meeting the international standards for an effective quality management system (QMS) to consistently provide value-driven products and services.

[P1vital @p1vital]

Our CEO and co-owner, Gerry Dawson, recently took part in a collaborative working group formed by @isctm and @ECNPtweets focused on insights derived from CNS trials conducted during the COVID-19 pandemic. Learn about the group's findings in their paper:
https://t.co/Jzt3QBrm2X

[P1vital @p1vital]

Happy birthday to the NHS! Celebrating 75 years of hard work and service to the nation from all those within the NHS, we couldn't be more grateful. #NHS75

[P1vital @p1vital]

Please note that the site will be updated and improved over time, so any comments or feedback are welcomed and appreciated.
We hope that you find the new P1vital website useful. (3 of 3)

[P1vital @p1vital]

P1vital is at the forefront of bringing clinical trials into the digital age and we are pleased to announce the launch of our new website. https://t.co/rAEPFq6krO (1 of 3)

[P1vital @p1vital]

This new site is the showcase for our eCOA platform, our neuropsychology-based technological developments and our research expertise. It will become the hub for all our new digital marketing activities, communications, articles and aligned with our social media channels. (2 of 3)

[P1vital @p1vital]

Our #IMI2PRISM2 team had a great time at the annual meeting in Madrid! Interesting discussions about next steps for the study, as well as ongoing analyses presented by our early career scientists. Many thanks to the organisers, can't wait to see everyone again soon!
@IMI2PRISM2

[PRISM 2 project @IMI2PRISM2]

Greetings from beautiful Madrid, where today and tomorrow the 3rd General Assembly of PRISM 2 is taking place. @IHIEurope #IMI2PRISM2 @MartienKas #Alzheimer #schizophrenia #biomarkers @EFPIA @cohenbioscience @EU_H2020

[P1vital @p1vital]

Only one week left to read and download this experimental medicine review on performance-outcome measures of orexin modulation for free!

[P1vital @p1vital]

A hot off the press experimental medicine review, co-authored by P1vital researchers, discusses how performance-outcome measures of orexin modulation can help bridge the gap between animal models and clinical efficacy. It's free for 50 days via this link: https://t.co/gEuOjCevwJ

[Intensive Care Society 💙 @ICS_updates]

Our GAINS study is still recruiting for phase 2.

We are running phase 2 of our research study looking to find out if a brief online intervention can reduce the number of intrusive memories someone may be facing as a result of working during the pandemic.

https://t.co/MmpJihMdaW

[P1vital @p1vital]

The ECNP workshop for early career scientists was a great opportunity for collaboration, with key questions asked about how we bridge the gap between clinical and pre-clinical in mental health, and provide real life benefit for patients #IMI2PRISM2 #ECNPWS2023 @ECNPtweets

[P1vital @p1vital]

Two of our scientists are excited to present posters at the #ECNP conference for early career researchers this weekend, one on treatment resistant depression and the other on the impact of social withdrawal on spatial learning and memory

[ECNP @ecnptweets]

Welcome to all participants and faculty members to the #ECNP Workshop for Early Career Scientists that is about to start in Nice☀️, France. We are waiting for you! @Dickson_Lab #BrainDisorders

[P1vital @p1vital]

Great to see a snapshot from our FERT (facial expression recognition task) in the news today as part of this article about the role of serotonin in depression https://t.co/mHGjkQ7Vbv

[P1vital @p1vital]

A hot off the press experimental medicine review, co-authored by P1vital researchers, discusses how performance-outcome measures of orexin modulation can help bridge the gap between animal models and clinical efficacy. It's free for 50 days via this link: https://t.co/gEuOjCevwJ

[P1vital @p1vital]

An excellent first day for the P1vital Science Team at the PRISM 2 General Assembly in sunny Mainz!

[PRISM 2 project @IMI2PRISM2]

Greetings from beautiful Mainz, where today and tomorrow the 2nd General Assembly of PRISM 2 is held.
https://t.co/dBsGQ1jOvm
#IMI2PRISM2 #Alzheimer #schizophrenia #biomarkers @IHIEurope @EFPIA @cohenbioscience @EU_H2020